172 related articles for article (PubMed ID: 35250884)
1. Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?
Rodier C; Courbière B; Fernandes S; Vermalle M; Florence B; Resseguier N; Brue T; Cuny T
Front Endocrinol (Lausanne); 2022; 13():832361. PubMed ID: 35250884
[TBL] [Abstract][Full Text] [Related]
2. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
[No Abstract] [Full Text] [Related]
3. PCOS and Hyperprolactinemia: what do we know in 2019?
Delcour C; Robin G; Young J; Dewailly D
Clin Med Insights Reprod Health; 2019; 13():1179558119871921. PubMed ID: 31523136
[TBL] [Abstract][Full Text] [Related]
4. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
5. Polycystic ovary syndrome and prolactinoma association.
Yavasoglu I; Kucuk M; Coskun A; Guney E; Kadikoylu G; Bolaman Z
Intern Med; 2009; 48(8):611-3. PubMed ID: 19367058
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
9. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
[TBL] [Abstract][Full Text] [Related]
10. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
Azziz R
J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211
[TBL] [Abstract][Full Text] [Related]
11. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
[TBL] [Abstract][Full Text] [Related]
12. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
Bozdag G; Mumusoglu S; Zengin D; Karabulut E; Yildiz BO
Hum Reprod; 2016 Dec; 31(12):2841-2855. PubMed ID: 27664216
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
15. [Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
Robin G; Catteau-Jonard S; Young J; Dewailly D
Gynecol Obstet Fertil; 2011 Mar; 39(3):141-5. PubMed ID: 21388855
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women.
Wongwananuruk T; Panichyawat N; Indhavivadhana S; Rattanachaiyanont M; Angsuwathana S; Techatraisak K; Pratumvinit B; Sa-Nga-Areekul N
Taiwan J Obstet Gynecol; 2018 Aug; 57(4):499-506. PubMed ID: 30122568
[TBL] [Abstract][Full Text] [Related]
17. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
[TBL] [Abstract][Full Text] [Related]
18. [The reaction of the hypophysis to thyroliberin and metoclopramide in women with hyperprolactinemia].
Tkachenko NN; Potin VV; Beskrovnyĭ SV; Nosova LG
Probl Endokrinol (Mosk); 1990; 36(2):35-40. PubMed ID: 2114023
[TBL] [Abstract][Full Text] [Related]
19. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria.
Franks S
J Clin Endocrinol Metab; 2006 Mar; 91(3):786-9. PubMed ID: 16418209
[TBL] [Abstract][Full Text] [Related]
20. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
